Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Role of Probiotic in Reducing Hepatic Inflammation Among NAFLD Patients: an Evidence-Based Case Report

ACTA MEDICA INDONESIANA · Vol. 48 No. 4 (2017) · hlm. 327–334

ISSN
2338-2732, 0125-9326
Terbit
2017-02-01
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Aim: to know the effectiveness of probiotic in reducing hepatic inflammation among non-alcoholic fatty liver disease (NAFLD) patients. Methods: we performed literature searching regarding the potential role of probiotic in reducing hepatic inflammation among NAFLD patients. Results: six articles were finally critically appraised. All six studies had good validity and importance. These studies unanimously reported that probiotic is useful in reducing hepatic inflammation, and liver fat content. However, further evidence is needed to show whether or not probiotic is beneficial reducing cirrhosis progression and liver-related mortality. Conclusion: probiotic owns robust potential to treat NAFLD. Probiotic reduce hepatic inflammation, as shown by the reduction of liver aminotransferase, and inflammatory markers. Based on this evidence based report, probiotic is a promising adjunct therapy for NAFLD.

Kata kunci

Jaringan kolaborasi para penulis

19 penulis · 88 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Irsan HasanAfiliasi tidak diketahui3
Juferdy KurniawanAfiliasi tidak diketahui3
Rino Alvani GaniAfiliasi tidak diketahui3
Chyntia Olivia Maurine JasirwanAfiliasi tidak diketahui3
Kemal Fariz KalistaAfiliasi tidak diketahui3
Andri Sanityoso SulaimanAfiliasi tidak diketahui2
Teguh SantosoAfiliasi tidak diketahui1
Puspita A KatiliAfiliasi tidak diketahui1
Andri SanityosoAfiliasi tidak diketahui1
Lutfie LutfieAfiliasi tidak diketahui1
Saut NababanAfiliasi tidak diketahui1
Rachmadianti Sukma HanifaAfiliasi tidak diketahui1
Desti RachmaniAfiliasi tidak diketahui1
Gita ApriliciaAfiliasi tidak diketahui1
Saut Horas Hatoguan NababanAfiliasi tidak diketahui1
Pitt AkbarAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Role of Probiotic in Reducing Hepatic Inflammation Among NAFLD Patients: an Evidence-Based Case Report</dc:title>
	<dc:creator>Nursalim, Alvin</dc:creator>
	<dc:creator>Madina, Ummi Ulfah</dc:creator>
	<dc:creator>Lesmana, Cosmas Rinaldi A</dc:creator>
	<dc:subject xml:lang="en-US">non-alcoholic fatty liver disease</dc:subject>
	<dc:subject xml:lang="en-US">NAFLD</dc:subject>
	<dc:subject xml:lang="en-US">probiotic</dc:subject>
	<dc:subject xml:lang="en-US">inflammation</dc:subject>
	<dc:description xml:lang="en-US">Aim: to know the effectiveness of probiotic in reducing hepatic inflammation among non-alcoholic fatty liver disease (NAFLD) patients. Methods: we performed literature searching regarding the potential role of probiotic in reducing hepatic inflammation among NAFLD patients. Results: six articles were finally critically appraised. All six studies had good validity and importance. These studies unanimously reported that probiotic is useful in reducing hepatic inflammation, and liver fat content. However, further evidence is needed to show whether or not probiotic is beneficial reducing cirrhosis progression and liver-related mortality. Conclusion: probiotic owns robust potential to treat NAFLD. Probiotic reduce hepatic inflammation, as shown by the reduction of liver aminotransferase, and inflammatory markers. Based on this evidence based report, probiotic is a promising adjunct therapy for NAFLD.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2017-02-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/265</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 48 No. 4 (2016): Acta Medica Indonesiana; 327-334</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/265/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2017 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>